The Antibodies Market is strongly influenced by the continued dominance of monoclonal antibodies. Market Research Future identifies monoclonal antibodies as the largest type segment, accounting for approximately 68% of the market.

These therapies are widely used because they can selectively interact with particular biological targets. This specificity makes them valuable in cancer treatment and the management of autoimmune and other chronic conditions.

Polyclonal antibodies represent another important category. Their ability to recognize multiple antigens gives them applications in therapeutics, diagnostics, and infectious disease research.

Intravenous immunoglobulin is also an established segment, particularly in applications requiring antibody replacement or immune modulation.

Continued advances in antibody engineering are creating opportunities for improved therapeutic characteristics, including greater specificity, longer duration of action, and potentially improved patient outcomes. These innovations are expected to support continued development of the antibody therapeutics landscape.